Redefining Strategic Planning for Modern Healthcare

1. When engaging with both private providers and public health systems, how do you adapt your strategic planning approach to align with their distinct governance, funding, and operational frameworks?

Our approach leverages Siemens Healthineers presence in over 70 countries, where we have staff deeply embedded in both private and public healthcare systems. These colleagues talk to many different market players daily. This local presence provides up-to-date knowledge on regulatory changes, reimbursement frameworks, and governance structures. We combine this with global guidelines, international best practices, and access to our network of financiers, regulators, and implementation partners. Of course, our global team leverages similar education, profiles and databases as the leading consulting firms in the world.

2. How do you ensure that early ideation translates seamlessly into practical, executable strategies that survive the transition from boardroom vision to patient-ready facilities?

Unlike pure-play consulting firms, we are part of a broader Siemens Healthineers ecosystem that spans from strategy to execution. This means early concepts are not left “on paper” but are continuously validated against real implementation capabilities, be it technology deployment, digital solutions, or workforce planning. Also, as we are part of Siemens Healthineers’ larger business mission, we must take into account that while our consulting advice is fully independent of Siemens Healthineers’ business motives, our colleagues will eventually be part of the implementation of the project.

3. Service-line positioning often determines long-term competitiveness. What frameworks or benchmarks do you apply to shape hub-and-spoke designs, referral flows, and clinical integration models effectively?

We use international benchmarks (e.g., CoE criteria, international referral benchmarks, and disease incidence/utilisation data) and adapt them to local realities. Our experience across Europe, MEA, and Asia provides a unique comparative database. For example, in the UAE, we designed a hub-and-spoke diagnostic model for a provider that drew on best practices from Singapore (specialty hubs) and Germany (integrated outpatient imaging centers) but tailored to the UAE’s payer environment and mall-based clinics. Similarly, we see that many of our customers do not want to just follow THE one global best-practice but rather integrate different successful models. This is one of the most value-adding scenarios for us: as our work truly spans across the globe, we can conclude both real-world experience and data that many of our team members gathered first-hand in different countries.

4. In building demand scenarios and financial models, how do you balance market-driven assumptions with clinical realities, especially in regions with volatile payer mixes?

We combine secondary data (epidemiology, insurance claims, and benchmarks) with local expert input (clinicians, payers, administrators) to validate assumptions. Every financial model is stress-tested with sensitivity and scenario analysis to account for volatile payer mixes and policy shifts. In Central Asia, for example, we modeled three demand scenarios (base, optimistic, and constrained) to account for currency fluctuations and uncertain insurance reforms. These scenarios are then further refined in the discussion with our customers, based on their experience, preference and the specific risks they want to take or avoid. As we stay part of the realization process, we are also able to adapt or update these models at a later stage, e.g. if financing institutions need more detail in specific areas.

5. Could you walk us through your methodology for aligning CAPEX/OPEX planning with long-term sustainability, while also maintaining clinical quality and patient accessibility?

For CAPEX, we start with a top-down view of incidence, prevalence, and competition to project demand, and combine it with a bottom-up assessment of workforce, infrastructure, and technology to ensure the system can realistically deliver against that demand. This prevents underutilised assets on one side and capacity bottlenecks on the other, keeping investments clinically relevant and financially sustainable. For OPEX, we anchor assumptions in local data to reflect true cost structures. For example, staffing costs make up a far higher share of operating expenses in high-income countries than in lower-income markets, ensuring projections remain both accurate and accessible for patients.

6. Many projects falter at the handover stage. How does your team ensure continuity when moving from strategic planning into pre-opening execution and operational readiness?

Our one-stop-shop model is a key differentiator: clients work with a single point of contact from ideation to implementation and long-term change management. We embed consulting into long-term partnerships, so-called Value Partnerships, ensuring the same team is accountable for pre-opening planning, operational readiness, and ongoing performance management. In practice, this avoids the “handover cliff” where strategy documents gather dust and ensures continuous accountability. We also find that this avoids inefficiencies in the consulting approach, as the team at each stage will be familiar with the discussions and assumptions that have been taken some time ago and therefore will not need to familiarize themselves with the models first.

7. What are the biggest risks you see in misaligned medical equipment planning or room/flow concepts, and how do you mitigate them early in the process?

The biggest risks are overinvestment in underutilised equipment (leading to financial strain) and bottlenecks in poorly designed patient flows. We mitigate this by combining robust demand forecasting with workflow simulation tools. For example, in Uzbekistan, we use patient-flow simulation for a new outpatient center to redesign the radiology reception area, avoiding future congestion and improving patient experience.

Here, our specialisation in healthcare really comes to play against generalist consulting firms: In a project in Mexico, the customer had planned a general hospital with a maternity ward for around 600 births/year. From experience, we found this to be rather high and checked for competition. It turned out that the neighboring clinic, which specialises in births, delivered around 550 births/year. Moving ahead with the assumption of 600 clearly wouldn’t have worked economically and capacity-wise.

8. In multi-vendor environments, what governance mechanisms do you implement to maintain accountability and integration across diverse stakeholders?

We establish structured program governance with a steering committee that includes all vendors, clinical stakeholders, and financial sponsors. We apply clear RACI matrices, standardised reporting, and performance dashboards. Independent “neutral facilitator” roles are often introduced to resolve conflicts. For instance, in PPP projects, we often chair multi-vendor governance forums, ensuring transparency across public partners, financiers, and technology providers. Being Siemens Healthineers as opposed to a generalist consultant makes it easier for us to play the role of integrator along the value-chain as we are used to dealing with a variety of different players within our complex projects.

9. How do you design ROI/NPV models that are robust enough for investors but still flexible enough to adapt to unexpected healthcare demand shifts?

We build ROI/NPV models on robust, clinically validated demand assumptions and complement them with sensitivity toggles for critical variables such as payer mix, utilisation rates, and price levels. This dual approach reassures investors by grounding projections in clinical reality, while also showing how margins and cash flows could evolve under different scenarios. In a project for an outpatient provider in Saudi, for example, we compared ROI across scenarios of in-house versus outsourced lab testing and imaging to see how capital intensity, staffing requirements, and reimbursement models would affect long-term sustainability. Similarly, in hospital network planning we model variations in referral capture rates to assess the resilience of the investment case against shifts in patient flows.

10. Can you share how case learnings from regions like the Middle East, Central Asia, and the Baltics have influenced your approach to building scalable, resilient healthcare networks?

In the Middle East, cultural factors like gender-segregated care models shaped referral design and staffing ratios. In Central Asia, volatile payer systems required conservative base-case assumptions with flexible growth options. In the Baltics, cross-border patient flows drove us to design multi-country referral networks. However, these are just some examples of different insights gained in the different geographies. Healthcare delivery and accessibility vary greatly across the globe: in the UK, with its NHS-driven market, partnership models with the public sector will be required to succeed, while in Mexico, private investment and physician commitment will play a key role.

11. What role does cultural and regulatory context play in shaping referral flows and clinical integration across different geographies?

Regulatory frameworks strongly shape integration. For instance, bundled payments and value-based care in Sweden and the US incentivise coordinated pathways, DRGs in most high-income countries drive hospital efficiency, while fee-for-service models in parts of Asia reinforce volume-driven care. Cultural factors are equally important for example, gender-sensitive care and strong family involvement in the Middle East influence referral flows and facility design, whereas in Northern Europe, patient autonomy and transparency are central. Both elements must be considered to design referral networks that work in practice.

12. How do you measure success beyond financial performance - specifically in terms of patient access, system resilience, and quality of care?

We integrate financial metrics with broader measures of healthcare performance, focusing on access, quality, and resilience. Access is evaluated through patient volumes, wait times, and geographic reach; quality is assessed using PROMs, adherence to clinical guidelines, and outcome indicators; and resilience is measured by the system’s ability to absorb shocks, such as pandemic readiness or workforce flexibility. For example, in Asia, oncology partnerships were evaluated not only on their return on investment but also on their success in reducing wait times for radiotherapy slots.

13. In your experience, what governance structures best support the “same team” model, where strategic planners remain engaged through implementation?

We establish joint steering committees to ensure the key point of contact stays the same from planning throughout the implementation phases. Escalation protocols, KPIs tied to both strategic and operational outcomes, and integrated PMO structures ensure transparency and continuity. In some cases, we embed consultants as interim PMO leads during hospital pre-opening phases, bridging the gap between planning and operations. This “same team” model not only secures consistent oversight but also builds trust with clinical and administrative leaders, reducing execution risk and accelerating time to readiness.

14. Finally, looking ahead, how do you see healthcare strategic planning evolving to reduce execution risk and accelerate time to service, particularly in emerging markets?

We see healthcare planning shifting toward comprehensive, end-to-end partnerships where execution risk is shared. Our value add is that Siemens Healthineers can combine strategy, technology, operations, and financing in one integrated offering, so hospitals don’t have to manage a fragmented set of consultants and vendors. By putting the patient journey at the center, rather than the provider’s internal structures, care models will be designed that are both clinically effective and financially sustainable. Leveraging digital tools such as AI-driven demand forecasting and workflow simulation further supports this approach, ensuring faster execution and reducing project risk.

--Issue 06--